Calcium carbonate as a phosphate binder in hemodialysis patients.
نویسندگان
چکیده
Calcium carbonate appears to be as effective as aluminum hydroxide in binding dietary phosphorus in hemodialysis patients. The long-term safety of this medication appears acceptable in view of today's therapeutic options.
منابع مشابه
Calcium Acetate Versus Calcium Carbonate as Oral Phosphate Binder: Preparation and In Vitro Assessment
Calcium acetate is used as an oral phosphate binder to control hyperphosphatemia in patients with chronic renal failure. Compared to calcium carbonate, control of hyperphosphatemia can be achieved at lower calcium administration with calcium acetate which likely reduces the risk of hypercalcemia. In this study, various formulations of calcium acetate tablets were prepared and their disint...
متن کاملComparison of Phosphate Lowering Properties of Calcium Acetate and Calcium Carbonate in Hemodialysis Patients
Hyperphosphatemia has an important role in the development of secondary hyperparathyroidism and bone disease in patients with end-stage renal disease (ESRD). The most effective method of phosphate elimination lies with phosphate binders, the agent that more commonly used, calcium carbonate, is not an ideal binding agent. In this regard, calcium acetate has been reported to have more or at least...
متن کاملEfficacy of crushed lanthanum carbonate for hyperphosphatemia in hemodialysis patients undergoing tube feeding
Lanthanum carbonate (LaC) is a non-calcium-based phosphate binder used to treat hyperphosphatemia in patients with chronic kidney disease. Oral administration of LaC is difficult in patients undergoing tube feeding or those who are of advanced age because it is essential to chew the LaC tablet sufficiently before swallowing it. We report two cases in whom crushed LaC was used in hemodialysis pa...
متن کاملLow Dose Nicotinamide as an Adjunctive Therapy to Calcium Carbonate for Control of Hyperphosphatemia in Hemodialysis Patients
Background: Hyperphosphatemia remains a common problem in patients on maintenance dialysis and contributes to the development of secondary hyperparathyroidism. Current therapies for the treatment of hyperphosphatemia are frequently insufficient to achieve the recommended K/DOQI goal of maintaining serum phosphorus level between 3.5 and 5.5 mg/dl. Niacinamide inhibits intestinal sodium/ phosphor...
متن کاملComparison of Phosphate Lowering Properties of Calcium Acetate and Calcium Carbonate in Hemodialysis Patients
Hyperphosphatemia has an important role in the development of secondary hyperparathyroidism and bone disease in patients with end-stage renal disease (ESRD). The most effective method of phosphate elimination lies with phosphate binders, the agent that more commonly used, calcium carbonate, is not an ideal binding agent. In this regard, calcium acetate has been reported to have more or at least...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- ASAIO transactions
دوره 32 1 شماره
صفحات -
تاریخ انتشار 1986